


# **ESRF Facility & User Program Overview**

# Joanne McCarthy Head of ESRF User Office



# **ESRF General Overview**



Location of facility : Grenoble, France

Ground-Breaking : January 1988

First Light : February 1992 (storage ring), November 1992 (beamline)

First official User Operation : September 1994 (8 beamlines)

Staff: 619 people work at ESRF (2012)

### Annual Budget :

ESRF Operation ~86 M€ (~90M€ Upgrade Programme over 2009-2015) User Budget ~1.4 M€ (6% budget reduction 2011-2013)



# **ESRF General Overview**

## Member and associate countries (as of July 2013)



Members' budget:	share in contribution	to the annual
27.5%	France	
25.5%	Germany	
15%	Italy	13%
14%	United Kingdom	10%
4%	Spain	
4%	Switzerland	
6%	Benesync (Belgium, Th	ne Netherlands)
4%	Nordsync (Denmark, F	inland, Norway,
	Sweden)	2 1 1 1 1

#### **Additional contributions**

(percentages refer to Members' total contribution):

- 1.3% Austria
- 1% Portugal
- 1% Israel
- 1% Poland
- 1.05% Centralsync (Czech Republic, Hungary, Slovakia)
- 0.3% South Africa April 2013



# **Beamlines at ESRF**

### Council Mandate : 30 public beamlines


1988	Ground Breaking	
1994	First user operation	8 public 3 CRG
1998	BL construction complete	30 public 12 CRG
2004	Maximum # of BLs	31.5 public 11 CRG
2013	6% budget reduction	29.5 public 9 CRG

SOURCE POSITION	NUMBER OF INDEPENDENT END-STATIONS	BEAMLINE NAME	STATUS
ID01	1	Microdiffraction imaging	Operational since 07/97
ID02	1	High brilliance	Operational since 09/94
ID03	1	Surface diffraction	Operational since 09/94
ID08	1	Dragon	Operational since 02/00
ID09	1	White beam	Operational since 09/94
ID10	1	Soft interfaces and coherent scattering	Operational from 06/12
ID11	1	Materials science	Operational since 09/94
ID12	1	Circular polarisation	Operational since 01/95
ID13	1	Microfocus	Operational since 09/94
ID14A	1	Protein crystallography EH 1	Operational since 07/99
		Protein crystallography EH 2	Operational since 12/97
ID14B	1	Protein solution small-angle scattering EH 3	Operational since 12/98
		Protein crystallography EH 4	Operational since 07/99
ID15A	1	High energy diffraction	Operational since 09/94
ID15B	1	High energy inelastic scattering	Operational since 09/94
ID17	1	Medical	Operational since 05/97
ID18	1	Nuclear scattering	Operational since 01/96
ID19	1	Topography and tomography	Operational since 06/96
ID21	1	X-ray microscopy	Operational since 12/97
ID22	1	Microfluorescence	Operational since 12/97
ID23	2	Macromolecular crystallography MAD	Operational since 06/04
		Macromolecular crystallography microfocus	Operational since 09/05
ID24	1	Dispersive EXAFS	Operational since 02/96
ID26	1	X-ray absorption and emission	Operational since 11/97
ID27	1	High pressure	Operational since 02/05
ID28	1	Inelastic scattering II	Operational since 12/98
ID29	1	Multiwavelength anomalous diffraction	Operational since 01/00
ID31	1	Powder diffraction	Operational since 05/96
BM14	1	Macromolecular crystallography (MAD)	Operational since 01/10
BM23	1	X-ray absorption spectroscopy	Operational since 03/11
BM29	1	Bio SAXS	Operational since 06/12

SOURCE POSITION	NUMBER OF INDEPENDENT END-STATIONS	BEAMLINE NAME	FIELD OF RESEARCH	STATUS
BM01	2	Swiss-Norwegian BL	X-ray absorption & diffraction	Operational since 01/95
BM02	1	D2AM (French)	Materials science	Operational since 09/94
BM08	1	Gilda (Italian)	X-ray absorption & diffraction	Operational since 09/94
BM20	1	ROBL (German)	Radiochemistry & ion beam physics	Operational since 09/98
BM25	2	SPLINE (Spanish)	X-ray absorption & diffraction	Operational since 04/05
BM26	2	DUBBLE (Dutch/Belgian)	Small-angle scattering	Operational since 12/98
			EXAFS	Operational since 06/01
BM28	1	XMAS (British)	Magnetic scattering	Operational since 04/98
BM30	2	FIP (French)	Protein crystallography	Operational since 02/99
		FAME (French)	EXAFS	Operational since 08/02
BM32	1	IF (French)	Interfaces	Operational since 09/94

Table 7: List of the Collaborating Research Group beamlines

Council Mandate : 30 public beamlines





# **ESRF Upgrade Programme**

Renew beamline portfolio of the ESRF with

minimum interruption of continued operation during the upgrade

Phase I (2009-2015)

Construction of Experimental Hall Extension, EX2 (completed June 2013)
 General shutdown from 5th December 2011 to 4th May 2012 (5 months)

3 classes of beamlines

UPBL beamlines:

Moving beamlines:

Non-moving beamlines:

8 UPBL projects,
15 independent endstations
2 fully reburbished + 2 moving I.Es
15 I.Es

2013 busiest year for beamlines; 8 I.Es currently unavailable



# **UP Phase I - Construction**

#### European Synchrotron Radiation Facility





# **UP** Phase I - Construction

#### European Synchrotron Radiation Facility





# **UP Phase I - Beamlines**

#### European Synchrotron Radiation Facility

Beamline Number	Original Beamline Name	Closure Date	Last Proposal Round	Last Scheduling Period	New Beamline Name	Opening Date	First Proposal Round	First Schedulin Period
ID01	Anomalous scattering Beamline	December 2013	Apr. 2013	2013/П		November 2014 tbc	Apr. 2014	2014/П
11002	High Brilliance Beamline - SAXS/WAXS/USAXS/Time-Resolved	July 2013	Oct. 2012	2013/I	High Brilliance Beamline	April 2014 the	Oct. 2013	2014/I
ID03	Surface Diffraction Beamline							
BM05	X-ray Imaging Beamline	April 2011	Oct. 2010	2011/I	Definitive closure as public beamline			
ID06	Not public beamline				Not public beamline following ID20 closure			
ID06-LVP	Not public beamline				Large Volume Press Beamline	September 2012	Apr. 2012	2012/II
ID08	Soft X-ray Spectroscopy Beamline	October 2013	Oet. 2012	2013/I				
ID09A	White Beam Station - High Pressure Beamline							
ID09B ID10A	White Beam Station - Time-resolved Beamline Troika I and III Beamline	December 2011	Arra 2011	2011/П	Becomes ID10	May 2012	Oct. 2011	2012/I
ID10A ID10C	Troika I and III Beamline	December 2011 December 2011	Apr. 2011 Apr. 2011	2011/II 2011/II	Definitive closure; Merged into ID10	May 2012	Oct. 2011	2012/1
ID10C ID10B	Troika I and III Beamline	December 2011	Apr. 2011	2011/II 2011/II	Definitive closure; Merged into ID10 Definitive closure; Merged into ID10			
ID10D	Materials Science Beamline	December 2011	Арг. 2011	2011/11	Definitive closure, Mergea into 1510			
ID12	Circular Polarisation Beamline							
ID13	Microfocus Beamline							
ID14-1	Structural Biology Beamline	November 2012	April 2012	2012/II				
ID14-2	Structural Biology Beamline	April 2010	April 2009	2009/II				
ID14-3	Bio-SAXS Beamline	December 2011	Rolling	2011/II				
ID14-4	Structural Biology Beamline		Apr. 2013	2013/II				
ID15A	High Energy Diffraction and Scattering Beamline							
ID15B	High Energy Diffraction and Scattering Beamline							
ID16A ID16B	ID16 - Inelastic X-ray Scattering Beamline	December 2011	Apr. 2011	2011/II	Nano-Imaging (ID16A) and Nano-Analysis (ID16B) (NiNa) Beamline	March 2014 January 2014	Oct. 2013 Apr. 2013	2014/I 2013/II
ID17	Bio-medical Beamline							
ID18	Nuclear Resonance Beamline							
ID22N	Nuclear Resonance End-Station	1st March 2011	Apr. 2010	2010/II	Definitive Closure			
ID19	High-Resolution Diffraction Topography Beamline							
ID20	Magnetic Scattering Beamline	May 2011	Apr. 2010	2010/II	Inelastic X-ray Scattering Beamline	May 2013	Oet. 2012	2013/I
ID21	X-ray Microscopy Beamline							
ID22	Micro-Fluorescence, Imaging & Diffraction Beamline	April 2013	Apr. 2012	2012/П	High-Resolution Powder-diffraction Beamline	April 2014	Oct. 2013	2014/I
ID18F	Microanalysis End-Station	1st March 2011	Apr. 2010	2010/II	Definitive Closure			
ID23-1	Structural Biology Beamline							
ID23-2	Structural Biology Beamline							
BM23	Not public beamline				X-ray Absorption Spectroscopy Beamline	March 2011	Oct. 2010	2011/I
ID24	Dispersive EXAFS Beamline	28th July 2010	Oct. 2009	2010/I	Dispersive EXAFS Beamline	May 2012	Oct. 2011	2012/I
ID26	X-Ray Absorption & Emission Spectroscopy Beamline							
ID27	High Pressure Beamline							
ID28	Inelastic Scattering II Beamline							
ID29	Structural Biology Beamline							
BM29	X-ray Absorption Spectroscopy Beamline	26th May 2010	Oct. 2009	2010/I	Bio-SAXS Beamline	June 2012	Rolling	2012/I
ID30A ID30B	Not public beamline				MASSIF Beamline - Screening Stations A-1, A-2, A-3	November 2013 tbc ???	Apr.2013	2013/II
ID30B ID31	Not public beamline High-Resolution Powder-diffraction Beamline	December 2013	Apr. 2013	2013/II	MASSIF Beamline - MAD Station B			
ID31 ID32	Surface XRD, SEXAFS and X-ray Standing Waves	December 2013	Apr. 2013 Apr. 2011	2013/II 2011/II	Soft X-ray Spectroscopy Beamline	March 2014 tbe	Oct. 2013	2014/I
BM01A	Swiss-Norwegian CRG Beamline : Diffraction							
BM01B	Swiss-Norwegian CRG Beamline : XAS and HRPD							
BM02	D2AM French CRG Beamline							
BM08	X-ray Diffraction and Absorption Beamline							
BM14	CRG MX Beamline		Apr. 2009	2009/II	ESRF/EMBL/INDIA MX Beamline		Oct. 2009	2010/I
BM16	Macromolecular Crystallography & SAXS/WAXS	December 2011	Oct. 2010	2011/I	Closed as Spanish CRG end of 2011; decommissioned from Summer 2011			
BM20	The Rossendorf CRG Beamline							
BM25A	Absorption & Diffraction CRG Beamline							
BM25B	Absorption & Diffraction CRG Beamline							
BM26A	DUBBLE - Dutch-Belgian CRG Beamline : EXAFS							
BM26B	DUBBLE - Dutch-Belgian CRG Beamline : SAXS/WAXS							
BM30A	French Beamline for Investigation of Proteins							
BM30B	Absorption Spectroscopy French CRG Beamline							
BM32	Surfaces & Interfaces French CRG Beamline							



# ESRF Upgrade Programme

Phase II : 2015 - 2020

2013 : Technical Design Study report in preparation in collaboration with user community, SAC and APAC

Storage ring replacement

> reduce horizontal emittance to  $\geq$ 100pm

would mean 1 year shutdown in 2018-2019


4 new upgrade beamlines

Vercors extension for up to 5 long beamlines





#### Proposals submitted and allocated beamtime, 2006-2013




Years

- 2011 & 2012 : ESRF General Shutdown + start of UP beamline work
- 2013 : Popular beamlines unavailable due to UP, e.g. ID22, ID02, ID08, some MX beamlines...




### Shifts of beamtime requested and allocated, 2006-2013





## Shifts allocated and delivered for experiments, User visits, 2006-2012






# **ESRF User Community**


## 2013 : NEW PROPOSAL REVIEW STRUCTURE !!

- **CH Chemistry**
- **ES Earth Sciences**
- **EV Environment**
- **HC Hard Condensed Matter**
- **HG Cultural Heritage**
- **LS Life Sciences**
- **MA Applied Materials**
- **MD Medicine**
- **ME Engineering**
- **MI Methods and Instrumentation**
- **MX Structural Biology**
- **SC Soft Condensed Matter**













# **ESRF User Community**





# **Categories of Proposals and Users**





## **REVIEWED PROPOSALS**


**STANDARD** Research Proposals

LONG TERM PROJECT Proposals

**MX BAG** Proposals


**MX Rolling** Proposals

## **Proposal Review Process**






## **Beamtime Application & Proposal Review**





## **Experiment Organisation**





**User Registration** Proposal submission Publication references Feasibility comments Grading **Review Committees Proposal acceptance** Scheduling Invitation letters A Form Safety training Sample sheets Safety evaluation User accommodations **Travel arrangements** 

EXPERIMENT

**Report submission** 

# **Proposal Workflow**

The typical workflow from user registration and proposal submission, through review process and scheduling until report submission

Each major task is supported by the SMIS User Portal



#### **User Registration User Office** User Proposal submission Publication reference **User Portal** Feasibility comments ESRF Accounts 👻 Proposals/Experiments - Safety -Administration 👻 Other Apps 🚽 Grading Manage ESRF User Portal (SMIS) account **Review Committees** -Select user to manage Type username's first letters MCCARTHY Joanne (ESRF) Proposal acceptance -Create a new user -Scheduling Create a new user -Account of Joanne MCCARTHY Invitation letters User Data Laboratory Reimbursement data A Form Title : Dr. Country : FRANCE Street name and number : Family name : MCCARTHY GRENOBLE City : City : Official name : Mccarthy Name : ESRF Country : Safety training First name : Joanne Address : Postal code : Gender : F 6 rue Jules Horowitz Personal e-mail : Sample sheets B.P 220 Country of nationality : UNITED KINGDOM I last updated this information on : Date of birth : 05/07/1972 Bank name : F - 38043 GRENOBLE Cedex Place of birth : London, UK Bank town : Safety evaluation Lab no.: 200450 +33(0)4 76 88 24 21 Phone : Bank postal code : Fax : +33(0)4 76 88 26 24 Bank country : User accommodation Email : mccarthy@esrf.fr Account in the name of : MCCARTHY Account no. : 216695 SWIFT code / BIC : Travel arrangements Staff no. : 010546 International Bank Account Number (IBAN) : Active staff : YES **EXPERIMENT** Manage this account Connect as user **Report submission**



Main Proposer

#### User Registration

# **Proposal submission**

S. 46					Connected as:	Joanne MCCARTHY 🦣 Home 🤹 Help 📣 FAQ 🤞	Contact 🥥 Sign out 🖃 F
					Connected as:	Joanne MCCARTHY 🥻 Home 🛸 Help 📣 FAQ 🦼	🕽 Contact 🥥 Sign out 🖃 H
ESRF	User Portal				Connected as:	Joanne MCCARTHY 🏠 Home 🔮 Help 📣 FAQ 🥃	🗲 Contact 🛛 Sign out 🖃 F
	Accounts   Proposals/Experiments  Safety  Administration  Other Apps  Electronic Utilities Application for ESRF Users						
	• From now on (20/07/2010) all su	iming at the CRG share of beamtime at uch proposals will be evaluated by the apply to standard ESRF proposals aimi ser	common French beamt	time allocation comr			
Click here to Change the nu	pus Proposals (view details, submit reports)         p see the proposals existing in the ESRF database.         umber of proposals shown :       5         m action related to a proposal, click on the appropriate icon.						
Click here to Change the nu	o see the proposals existing in the ESRF database. umber of proposals shown : 5	Туре	Round	Report	Beam	Actions	
Click here to Change the nu To carry out ar	osee the proposals existing in the ESRF database.         umber of proposals shown :         5         an action related to a proposal, click on the appropriate icon.             Title	Type CRG DUBBLE-BM26B	Round 4/2008	Report	Beam Y	Actions View proposal details Manage your Experiment Report Manage your samples :	Q 13 1
Click here to Change the nu To carry out an Code 26-02 438	posee the proposals existing in the ESRF database. umber of proposals shown : 5  in action related to a proposal, click on the appropriate icon.  Title  Main proposer Wim Bras Reorientation processes in high order liquid crys	CRG		Report		View proposal details Manage your Experiment Report	<b></b>
Click here to Change the nu To carry out ar Code 26-02 438	see the proposals existing in the ESRF database.     umber of proposals shown : 5      im action related to a proposal, click on the appropriate icon.     Title	CRG DUBBLE-BM26B	4/2008	Report		View proposal details Manage your Experiment Report Manage your samples : View proposal details	1 \ Q
Click here to Change the nu To carry out an Code 26-02 438 HE 1013	see the proposals existing in the ESRF database.     umber of proposals shown: 5      in action related to a proposal, click on the appropriate icon.      Title          Main proposer Wim Bras         Reorientation processes in high order liquid crys          · Main proposer Malcom Cooper         Study of the Sm spin density in SmMn2Ge2         · Main proposer Andrew Bebb         Temperature dependence of sub-lattice magnetisati          Aution proposer Malcom Cooper         Study of the Sm spin density in SmMn2Ge2         · Main proposer Andrew Bebb         Temperature dependence of sub-lattice magnetisati          Aution proposer Malcom Cooper         Study of the Sm spin density in SmMn2Ge2	CRG DUBBLE-BM26B STD	4/2008	Report		View proposal details Manage your Experiment Report Manage your samples : View proposal details Manage your Experiment Report View proposal details	() () () () () () () () () () () () () (

Report submission



**Beamline Responsible** 


#### **User Registration**

Proposal submission


#### Publication references

SMIS Schedule View Page - Windows Internet Explorer Feasibility comments G 💌 🎄 http://jmis1:8080/misapps/SMISWebClient/protected/scheduling/viewSchedule.do?action=rolToNextWeek&week=58run=61&year=2008&includeCancelled=false&includeInhouse=true&beamline 🔻 🍫 🗙 Google ρ. 🟠 🔹 🔝 👻 📥 🔹 🔂 Page 🔹 🙆 Tools 🔹 🚖 🏟 🧟 SMIS Schedule View Page Grading Welcome Stefan Schulze 🄎 8 **TEST SMIS Web Client** ESRF **Review Committees** Accounts Experiments Reception Treasury Travel Safety Other Applns 🛙 < Week 6 🕨 📆 Run 1/08 🔁 Experiments Proposal acceptance Year: 2005 2006 2007 2008 2009 Week: 3 4 5 6 7 8 9 10 11 12 13 Cancelled: C Hide C Show IHR & BLC: C Hide C Show Proposals Run: 1/08 2/08 3/08 4/08 Manage Proposals Monday, Tuesday, Wednesday, Thursday Friday, Saturday, Sunday, A Forms Scheduling 4 Feb 2008 5 Feb 2008 6 Feb 2008 7 Feb 2008 8 Feb 2008 9 Feb 2008 10 Feb 2008 ID11 💌 🕄 ⊗ ID11 Run 1/08 finalized 2 **ESRF/ILL Library** • MDT **ONO** MDT æ 16 Bunch 90mA œ 16 Bunch œ 16 Bunch Ð Ð NOBLC-3828 Manage Schedule Invitation letters BLC  $\otimes$ <u>HS-3423</u>  $\otimes$ <u>HS-3423</u>  $\otimes$ <u>HS-3423</u> 8 HS-3423 8 Show Finalized Runs 08:00 LC: G. VAUGHAN LAUSI LAUSI LAUSI LAUSI J. WRIGHT J. WRIGHT J. WRIGHT J. WRIGHT BLC-3828 16:00 Θ Θ G. VAUGHAN A Form 0 0 © 0 0 0 0 •No / æ 16 Bunch 90mA Ð MDT MDT Đ 16 Bunch 90r Đ 16 Bunch 90n Đ œ BLC-3828 8  $\otimes$  $\otimes$ <u>HS-3423</u> <u>HS-3423</u> 8 <u>HS-3423</u> <u>HS-3423</u> 😣 <u>BLC</u> Safety training 16:00 LC: C. VAUGHAN LAUSI LAUSI LAUSI LAUSI . WRIGHT J. WRIGHT J. WRIGHT J. WRIGHT BLC-3828 Θ Θ Θ Θ 24:00 G. VAUGHAN C O 0 0 C C 0 Sample sheets æ 16 Bunch 90mA Ð MDT •No MDT œ 16 Bunch 90mA æ 16 Bunch 90mA • 16 Bunch 90mA æ **BLC**  $\otimes$ BLC-3828 HS-3423 8 HS-3423 ⊗ <u>HS-3423</u>  $\otimes$ <u>HS-3423</u>  $\otimes$ 00:00 C: G. VAUGHAN LAUSI LAUSI LAUSI LAUSI Safety evaluation J. WRIGHT J. WRIGHT . WRIGHT J. WRIGHT BLC-3828 Θ A Θ 08:00 G. VAUGHAN © 0 0 0 0 C 0 User accommodations Invitation letter sent Invitation letter must be re-sent Experiment color: Add beamline: -Help . Go to day: FAQ **Travel arrangements** Logoff Click her for HELP **EXPERIMENT** Copyright © 2006 ESRF

**Report submission** 














Main Proposer



#### **User Registration**

Proposal submission

Publication references

🦉 SAMPLE :

O ESRF

Copyright

Feasibility comments

Grading

**Review Committees** 

Proposal acceptance

Scheduling

Invitation letters

A Form

Safety training

## **Sample sheets**

Safety evaluation

User accommodations

Travel arrangements

EXPERIMENT

**Report submission** 

	SMIS Web Client
	/
Sample #: 212	SAMPLE INFORMATION & SAFETY SHEET * = Mandatory Field. 9 = Tooltip. = Read-Only Field.
Proposal / Experiment #: MX-	
	Complete all tabs prior to submission!
Description Handling / E	Equipment Certify And Save
Text Description of Sample and P	Protein*
Sample Description: TEST s	sample for MIS group Protein Acronym: skjbd (?)
Classification Of The Substance*	
Tissue	
Crystal If Power Powder	der or Solution, concentration and/or amount of substance:
In Solution If Tissu	ue or Other, please specify:
	ue or Other, please specify:
In Solution If Tissu	ue or Other, please specify:
In Solution If Tissu Other	
In Solution Other If Tissu Classification Of The Sample* Radioactive Contamine	ent 🔽 Toxic 🔲 Flammable 🔲 Explosive 🗖 Corrosive 🗖 Oxidizing 😿 Synthetic
Classification Of The Sample*	ent 🔽 Toxic 🔲 Flammable 🔲 Explosive 🗖 Corrosive 🔲 Oxidizing 💌 Synthetic
In Solution Other If Tissu Classification Of The Sample* Radioactive Contamine Biological Other (give a	ent 🔽 Toxic 🔲 Flammable 🔲 Explosive 🗖 Corrosive 🔲 Oxidizing 😿 Synthetic
In Solution Other If Tissu Classification Of The Sample* Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample*-	ent 🔽 Toxic 🔲 Flammable 🔲 Explosive 🗖 Corrosive 🗖 Oxidizing 😿 Synthetic
In Solution Other If Tissu Classification Of The Sample+ Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample+ Source Organism+12	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class Of Risk+ Class 1: biological agent unikely to cause human disease
In Solution Other If Tissu Classification Of The Sample+ Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample+ Source Organism+12	ent Toxic Flammable Explosive Corrosive Oxidizing V Synthetic a short explanation): Class Of Risk*
In Solution If Tissu Other	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class Of Risk+ Class 1: biological agent unlikely to cause human disease () Class 2: biological agent that can cause human disease
In Solution Other If Tissu Classification Of The Sample+ Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample+ cource Organism+12) IIS group	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class Of Risk+ Class 1: biological agent unlikely to cause human disease Class 2: biological agent that can cause severe human disease Class 3: biological agent that can cause severe human disease (prophylaxis, treatment available)
In Solution Other If Tissu Classification Of The Sample+ Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample+ cource Organism+12) IIS group	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class Of Risk + Class 1: biological agent unlikely to cause human disease Class 2: biological agent that can cause severe human disease (rophylaxis, treatment available) Class 3: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) (If yes: "Expression Host" and "Class Of Risk"; below must be provided) Class Of Risk +
In Solution Other If Tissu Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample + ource Organism + 12) Its group s the sample recombinant? +	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class 1: biological agent unikely to cause human disease Class 2: biological agent that can cause human disease Class 3: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 5: Thological agent unikely to cause human disease
In Solution Other If Tissu Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample + ource Organism + 12) Its group s the sample recombinant? +	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class 1: biological agent unlikely to cause human disease Class 2: biological agent that can cause human disease Class 3: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that cause severe human disease (no prophylaxis, treatment available) (If yes: "Expression Host" and "Class Of Risk"; below must be provided) Class 1: biological agent that cau cause human disease Class 3: biological agent that can cause severe human disease Class 3: biological agent that can cause severe human disease Class 3: biological agent that can cause severe human disease Class 3: biological agent that can cause severe human disease Class 3: biological agent that can cause severe human disease (prophylaxis, treatment available)
In Solution Other If Tissu Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample + Fource Organism + 12) Its group State Sample + Source Organism + 12	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class Of Risk + Class 2: biological agent unikely to cause human disease Class 3: biological agent that can cause human disease Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (no prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (no prophylaxis, treatment available) Class 1: biological agent unikely to cause human disease Class 1: biological agent unikely to cause human disease Class 1: biological agent unikely to cause human disease Class 1: biological agent unikely to cause human disease Of Class 2: biological agent unikely to cause human disease
In Solution Other If Tissu Classification Of The Sample+ Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample+ ource Organism+12) Its group s the sample recombinant?+ Expression Host+12)	ent Toxic Flammable Explosive Corrosive Oxidizing V Synthetic a short explanation): Class 1: biological agent unlikely to cause human disease Class 3: biological agent that can cause human disease Class 3: biological agent that can cause severe human disease (no prophylaxis, treatment available) Class 4: biological agent that cause severe human disease (no prophylaxis, treatment available) (If yes: "Expression Host" and "Class Of Risk"; below must be provided) Class 1: biological agent that cau cause human disease Class 3: biological agent that cau cause severe human disease Class 3: biological agent that cau cause severe human disease Class 3: biological agent that cause severe human disease Class 3: biological agent that causes severe human disease Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available)
In Solution Other If Tissu Classification Of The Sample+ Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample+ ource Organism+12) Its group s the sample recombinant?+ Expression Host+12)	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class 1: biological agent unikely to cause human disease Class 2: biological agent that can cause human disease Class 3: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) (If yes: "Expression Host" and "Class Of Risk"; below must be provided) Class 1: biological agent that cause severe human disease Class 1: biological agent that cause severe human disease Class 1: biological agent that cause severe human disease Class 2: biological agent that cause severe human disease Class 3: biological agent that cause severe human disease Class 3: biological agent that causes severe human disease (prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available) Class 4: biological agent that causes severe human disease (no prophylaxis, treatment available)
In Solution Other If Tissu Classification Of The Sample + Radioactive Contamine Biological Other (give a Synthetic Or Biological Sample + ource Organism + 12) Its group = s the sample recombinant? + ( Expression Host + 12) = Provide the maximum containment	ent Toxic Flammable Explosive Corrosive Oxidizing Synthetic a short explanation): Class Of Risk+ (Class 2: biological agent unikely to cause human disease Class 3: biological agent that can cause severe human disease Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) (If yes: "Expression Host" and "Class Of Risk"; below must be provided) Class 1: biological agent unikely to cause human disease (Class 1: biological agent unikely to cause human disease (Class 2: biological agent unikely to cause human disease (Class 2: biological agent unikely to cause human disease (Class 2: biological agent that can cause severe human disease (Class 2: biological agent that can cause severe human disease (Class 2: biological agent that can cause severe human disease (Class 2: biological agent that can cause severe human disease (Class 2: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) Class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) class 4: biological agent that can cause severe human disease (prophylaxis, treatment available) (biological agent that can cause human disease (prophylaxis, treatment available) (biological agent that can cause human disease (prophylaxis, treatment available) (biological age

Safety Officer



User Registration Proposal submission Publication references Feasibility comments Grading Review Committees Proposal acceptance

Scheduling

Invitation letters

A Form

Safety training

Sample sheets

## **Safety evaluation**

User accommodations

**Travel arrangements** 

EXPERIMENT

**Report submission** 



	Accounts - Proposals/Experiments -	- Reception - Safety - Admi	nistration 👻 Review Process 👻 Other A	pps 👻		
pdate prop	oosal comments					
ороваі	MX - 1194					
	Expert> Select	▼				
	Accounts - Proposals/Experiments - Rec	eption 👻 Safety 👻 Administration	- Review Process - Other Apps -			
icome to th	e Electronic Utilities Application for ESR	F Managers				
Criteria for extrai	ction of Forms A and Sample Sheets Data					
	Start Dates of experiments between	<b>b</b>	AND			
	Deamline(s) ⑦ ID ID		Proposal Round(s)@	2011/4 * 2010/10 2010/4 *	Proposals MX	gory from to
	The beamlimes should be treated as Ac	Clear fillers Refresh Let	Search through scheduled experiments WITH	OUT COLOUR only?		
Result					Electronic de la companya de la comp	2
Proposal	Experiment Session	Assign Exp. Session Colour	Print SAF	Samples for the Experiment Session (Form A)	Other samples linked to the proposal	12
MX 1039	022-5-02-3eo-701004-3eo-2010	Green	Temptate Select 💌 Print Select	Airport Form: FR II GD 50 • CK2 Airport Form: FR II GB 55		
	022-1-06 Sep 2010 - 07 Sep 2010	Yellow	Template Select  Print	Utild dependent strote	OtiA depandent prote      OtiA depandent prote     OtiA reseator     phonodoritin sulphat     OtiA     CKZ	II
				Airport Form : FR  G8  G8	DNA ligase IV.XRCC4 ②     DNA ligase IV.XRCC4 ③     DNA ligase IV.XRCC4 ③     DNA repair XLF-XRCC ④	
	1023-1.06 Sep 2010 - 09 Sep 2010	Yellow	Template Select 💌 Print	DNA liquese IV-XRCC4@     DNA liquese IV-XRCC4@     Hepatocyte Growth F@	Hepatocyte Growth F	
	023-1 08 Sep 2010 - 09 Sep 2010 1023-2 16 Sep 2010 - 17 Sep 2010	Yellow	Template Select   Template Select	DNA ligase IV-XRCC4     DNA ligase IV-XRCC4	Hispationyte Growth F	
				DRA Boase IM-XRCC4.      DRA Boase IM-XRCC4.      DRA Boase IM-XRCC4.      Hepotexte Sorowh E      Arport Form: FR      G8      Pantotherate synths	Hepatocyte Growth F	
	003-2 16 Sep 2010 - 17 Sep 2019 ID 14-1 04 Nov 2010 - 05 Nov 2010 Bit1 4U 02 Dec 2010 - 03 Dec 2010	Green • None • None •		Other Leases CHARGES Composition of the Lease of MARGES Composition of the Lease of MARGES Composition of the Lease o	Hepatocyte Growth F	
MX 1040	1023-2: 45 Sep 2010 - 17 Sep 2010 1014-1 84 Nov 2010 - 05 Nov 2010	Green 💌		OthA loase //XRC54_@     OthA loase //XRC	Hepatocyte Growth F	_



**User Registration** Proposal submission Publication references Feasibility comments Grading **Review Committees** Proposal acceptance Scheduling Invitation letters A Form Safety training Sample sheets Safety evaluation User accommodations Travel arrangements **EXPERIMENT** 


**Report submission** 

# **Finally: The Experiment!**











0 Q.

er

nts.

# **Reports & Publications**

User	Eva	luation	n Form
------	-----	---------	--------


by Marie Robichon - last modified 07-09-2010 16:08

This form is to be completed by each user team coming to carry out an experiment at the ESRF. Details which you fill in will be transmitted to the appropriate members of staff and the Users Organisation, and summaries of the responses will be made for ESRF Management and for the Science Advisory Committee.

= OBL	.IGA	Use of PL TION to PUBL	Experiment No:   Experiment No:   Experiment No:   Local contact:  Name + Surname		
Reporting  Users allocat each experimer  forwar forwar require  There is also a their experiment, and support from	Report:	failures and reas	sons for	failures	Shifts allocated: • Shifts scheduled: • Shifts scheduled: • Shifts used: • Shifts used: • Shifts used: • Indicate the degree of success of your experiment: • Very Successful Satisfactory Fell below expectations Unsuccessful If less than satisfactory, please estimate the total time lost: Please give reason for any time lost: Please give reason for any time lost: Achine or storage ring failure Failure of beamline components Computer failure Sample Problems Other Details concerning time loss:
					What measures could be taken to improve the effectiveness of your beamtime ?




# **Publications**





# **Staffing – User Administration**





### Proposal Review

- printing proposals (UO, beamline scientists, committees, Directors, Safety), contacting incomplete submissions, organisation of BTAP meetings (contact members, registration, accommodation, local transport...), correspondence (acknowledgement, decison letters).....
- proposal assignment to committees, management of LT proposals, contact with committee members, compilation of data (TF assessments, grades) for panel meetings, fair scientific return and pro rata calculations, processing of results of panel meetings, rejection comments......

## Experiment Organisation

validation of beamline schedules, invitation letters, experiment modifications in database, protocols, visa requests, validation of reimbursement claims, pre-validation of all non-standard requests (submitted via email or A-Form), proposal management & archiving....

## User Meeting & other workshops

- SMIS tests & validation
- Statistics & Reports

### General User Administration

- account and laboratory validation
- User Web pages
- BAG administration (groupings, correspondence...)
- Follow-up of LTP reports
- Questions & Queries

- Scientific Use for Council
- DG Report for AFC (full 6-monthly stats)
- Beamline Review Panels
- Annual Highlights
- BTAP summaries....



# **The Business Development Office**

> Dedicated point of contact and organisation for all industrial activities


- proprietary beam time and customised R&D services (inc. contract research)
- patents, licences
- collaborations with industry
- encouraging industry to use peer review time and LTPs
- pre-competitive procurement opportunities (more of a wish than reality so far)
- education and training for industry
- joint (national, European) grants and partnerships with industry (inc. PhDs etc)
- building alliances for a better service to industry
- engineers/scientists for MX and Imaging

Self-financing (<10% of total income)</p>

About four full-time equivalents








2011: 2.2MEuros income generated
Beam access by industry represents about 2% of beam time capacity; but about 10% of allocatable income



# **BDO manages whole process with industry**



### **Beamtime Constraints**

- < 10% of total beamtime available</li>
- < 30% of beamtime available on single public beamline
- currently have no beamline for 100% PR but could have if requested



## **APPLICATION FORMS : NON-PEER REVIEWED**

NON-MACROMOLECULAR CRYSTALLOGRAPHY Experiments ("IN")

MACROMOLECULAR CRYSTALLOGRAPHY Experiments ("IX")

			Connected as: Joanne MCCARTHY 🕋 Umbrella 🧑 Home
	User Portal		
FOR			
<u>ESRF</u>	Accounts   Proposals/Experiments  Safety  Administration  Review Process  Other Apps		
Welcome to t	he Electronic Utilities Application for ESRF Users		
🖗 Note for Indu	strial clients		
You si	nould consider the term "Proposal" throughout as an "Experiment"		
New Proposal	Proposals In progress Proposals with Final Number/Previous Proposals In progress, as Co-Proposer		
Information fo			
	consult the Information on Data Provided concerning Scientific Use of ESRF At Deadline for the submission of Standard ESRF proposals is: Sunday, September 01 2013 (inclusive)		
The ne	xt Deadline for the submission of Long Term Project proposals is: Wednesday, January 15 2014 (inclusive) creating your proposal, make sure that each co-proposer has created his(her) account.		
• Delore	dealing four proposal, make sure mar each co-proposel has dealed instrier) account.		
-Submit New I	Proposal		
To create you	r Beamtime Application Form, select the appropriate Proposal by clicking on the corresponding button.		
. 🔘	Standard ESRF Proposal 😰		
• 🔘	Structural Biology : Rolling Proposal 😰		
• 🔘	Structural Biology : BAG Proposal 😰		
• 🔘	Long-Term Project 😰		
• 🔘	CRG Proposal 👰		
• ()	Industrial Experiment ( Non Macromolecular Crystallography) 🕅		
• 🔍	Industrial Experiment ( Macromolecular Crystallography ) 🕅	Please select :	
			Experiment to be carried out by ESRF Staff
			Experiment to be carried out by Industrial Client



## **Users' Organisation**

Made up of representatives of the ESRF User community

Members elected by User community (7 scientific areas)

Report to Scientific Advisory Committee and Management every 6 months on feedback from Users, organise the ESRF Users Meeting in conjunction with User Office

### The Users Organisation Committee (UOC)

<u>Thomas Buslaps</u> (ESRF) - ESRF local liaison <u>Paola Coan</u> - X-ray imaging <u>Olivier Diat</u> - Soft matter structures <u>Christian Kumpf</u> - Surface and interface science <u>Chiara Maurizio</u> (chairperson) - Structure of materials <u>Claudio Mazzoli</u> - Electronic structure and magnetism <u>Chrystele Sanloup</u> - Dynamics and extreme conditions <u>Beatrice Vallone</u> - Structural biology

## **User Meeting**

Annual ESRF Users' Meeting associated with 2-3 satellite workshops

Takes place typically in February each year

More than 300 users attend the Users Meeting



# **Education & Outreach**

UP	Home / About Us / Press room		General news
Organisation			Good vibrations:
Synchrotron science	Press room	(Q	students rate the ESRF Sea squirt solves crystal
ESRF Upgrade Programme			conundrum ESRF hosts
Services	02-05-2013		Matchmaking between Dutch Industry and
Press room	Dear journalist,		Grenoble R&D companies
<ul> <li>ESRF quick facts for journalists</li> </ul>	Please do not hesitate to contact press@esr1.fr or +33 4 7688 2128 for any query. W get back to you on the same day.	/e will do our best to	
<ul> <li>Introduction to the ESRF for Journalists</li> </ul>	If you wish to receive ESRF press releases (about ten per year), please send a brief press(@esrf.fr and mention whether you wish to receive these in English, French or it		ESRFnews
Information material	To arrange an Interview with an ESRF scientist by telephone or email, or to arrange a		Subscribe to the
Ask an expert	contact us at press@esrf.fr or, if it is urgent, call +33 666 662 384.		free digital edition
Campus and directions	Claus Habfast Head of Communications		Documents and videos
Visit an Institute			E\$RFnews
	Resources for journalists		Highlights A Light for Science
	ESRF quick facts		Synchrotron X-ray Solutions for Industry
	Introduction to ESRF for Journalists		Science and Technology Programme 2008-2017
	Images [new window]		ESRF Video Presentations
	Videos [new window]		Presentations
	Broadcast quality files: please contact Claus Habfast		more
of the Dutch Ambassador and other prestigious gues more than 20 hi-tech companies from The Netherland displayed their products and expertise in the newly inaugurated Belledonne experimental hall of the ESRF Read more		Static and dynam compression of	metals rotron trons/funding bodies)
More News	Read more	Effects of dilutin sublattice on the	

Q

Events

eminars

Fe-based

radiation

superconductors

Static and dynamic

compression of metals

probed by synchrotron

HSC15: Synchrotron

X-ray imaging for Biology

The local structure of the



# **Education & Outreach**

UP

## **Printed Publications**

- ESRFnews
  - news magazine pu
  - nearly 10000 subs ser
- ESRF Highlights
  - > annual report
  - 3500 print copies -
- Specific brochures

e.g. in 2013, impaction, e



Ask an expert

Visit an Institute

Campus and directions



18-06-2013

Home / About Us / Information material

Information material

ESRFnews, our online news magazine published four times a year, reflects ongoing scientific and technical developments. Each issue features a focus topic. Subscription is free of charge.

ESRF Highlights give a concise overview of scientific and technical progress. It is published annually in print and online versions. Subscription is free of charge.

ESRF Videos, span a range of subjects and lengths and are also available on a YouTube channel Light for science.

## **Visitors Centre**

- Currently 4000 visitors |
- Scientists and non-scier
- Have capacity for up to
- New Visitors Centre with







ESRF Brochures give an overview of the facility and present applications of synchrotron light, in several languages, in the form of PDF files.

A collection of high-quality images from the ESRF can be found in the image bank of Lightsources.org.



# Thank You for your attention!

insu unitation